Cancer BiologybioRxiv
Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency
M. Werner-Klein, A. Grujovic, C. Irlbeck…·C. A. Klein
The paper identifies IL6 trans-signaling as a mechanism supporting DCC survival and outgrowth during clinical latency, with microenvironmental dependencies and PIK3CA mutations linked to metastatic progression.
DOI 10.1038/s41467-020-18701-4